Genentech, Inc.
Phase III C-08 Study of Avastin in Early-Stage Colon Cancer Did Not Meet Primary Endpoint
Published in Cancer Weekly, May 12th, 2009
Genentech, Inc. announced that a Phase III study of Avastin® (bevacizumab) plus chemotherapy following surgery in patients with early-stage (adjuvant) colon cancer (NSABP C-08) did not meet its primary endpoint of reducing the risk of cancer returning (improvement in disease-free survival). Results are from a planned final analysis of the study. This is the first trial of Avastin in early-stage cancer and results do not affect approved indications in advanced (metastatic) disease.
Safety findings were consistent with those presented from this study at the 2008 American Society of Clinical Oncology (ASCO) annual meeting (Allegra et al.). Data from the trial have been...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2009-05-12)
More Articles from Cancer Weekly
- American Institute of Physics
Simulated gene therapy - Advaxis, Inc.
Advaxis Applies for Approximately $1.0 Million Worth of Grants from the National Institute of Health - Angiogenesis
Researchers from Musashino University report on findings in angiogenesis - Antiretrovirals
New antiretrovirals findings from New York University published - Ardea Biosciences, Inc.
Ardea Biosciences and Bayer HealthCare Enter into Global Agreement Focused on the Development of MEK Inhibitors for the Treatment of Cancer - Array BioPharma Inc.
Array BioPharma’s ARRY-520 Demonstrates Significant Activity in Hematological and Taxane-Resistant Tumors - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
